Ittero Therapeutics is a start-up pharmaceutical company with the mission of developing and commercializing treatments for rare genetic disorders caused by DNA Trinucleotide Repeat Expansions prevalent in >20 diseases. We will leverage recent groundbreaking target validation data in cellular and animal models of Friedreich’s Ataxia (FRDA) to develop first in-class disease modifying molecules to enter the clinic in less than 3 years.